---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-071465"
form_type: "8-K"
ticker: "VIVS"
cik: "0001497253"
company_name: "VivoSim Labs, INC."
filed_at: "2023-03-15T23:59:59+00:00"
generated_at: "2026-06-18T01:55:53.180348+00:00"
event_type: "m_and_a"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Organovo acquires Metacrine's FXR program for $4M cash

## Summary
- Total cash consideration of $4M; $2M paid at closing and $2M due after transfer of program.
- Acquired FXR program from Metacrine, targeting NASH and liver diseases.
- Purchase Agreement entered into and closed on March 10, 2023.
- Customary representations, warranties, and closing conditions included.

## SEC filing metadata
- accession: 0001193125-23-071465
- form_type: 8-K
- ticker: VIVS
- cik: 0001497253
- company_name: VivoSim Labs, INC.
- filed_at: 2023-03-15T23:59:59+00:00
- event_type: m_and_a
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 1.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1497253/000119312523071465/0001193125-23-071465-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1497253/000119312523071465/d401508d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-071465
- JSON: https://secwatch.observer/filing/0001193125-23-071465.json
- Plain text: https://secwatch.observer/filing/0001193125-23-071465.txt

## Key facts
- Material Agreements
  VivoSim Labs, INC. entered into Purchase Agreement with Metacrine, Inc. valued at $4 million (effective 2023-03-10).
  - Action: entry
  - Agreement: asset purchase
  - Counterparty: Metacrine, Inc.
  - Value: $4 million
  - Effective: 2023-03-10
  source text: On March 10, 2023, Organovo, Inc. (“Organovo”), a wholly-owned subsidiary of Organovo Holdings, Inc., entered into and closed an asset purchase agreement (the “Purchase Agreement”) with Metacrine, Inc. (“Metacrine”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1497253/000119312523071465/0001193125-23-071465-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.